This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The End of Blockbuster Drugs

As Pfizer's (PFE - Get Report) Celebrex safety hiccup was unfolding Friday, I had a running conversation with a fund manager. Over the course of several phone calls and instant messages, this fund manager vented his frustration, arguing that from a medical and scientific standpoint, the Celebrex scare was overblown.

At the proper (low) dosages, Celebrex wasn't causing an increased risk of heart attack or stroke, he argued. And he felt that as long as Pfizer kept the drug on the market (which he was confident would happen), doctors would continue to prescribe it to their patients.

This fund manager is a smart guy, but he's in the dark about what's really going on with Pfizer right now. There is a public hysteria over Celebrex and the entire class of so-called COX-2 inhibitors . People are scared that if they pop a Celebrex, a Vioxx or a Bextra in their mouths, they're going to keel over from a heart attack! Blame the media or the tort lawyers for inciting this fear -- it doesn't matter. Because right now, as far as Wall Street is concerned, Celebrex sales are balanced precariously on a cliff whether or not the drug is ultimately pulled from the market. (Can you imagine a doctor prescribing Celebrex these days?)

Jim Cramer gets it when he asked on Monday why, according to Pfizer, is Celebrex safe enough to sell to the public, but not safe enough to advertise on television? The Food and Drug Administration -- already under withering criticism for what it did, or didn't do, about Merck's (MRK - Get Report) Vioxx safety problem -- doesn't seem to be in a position to go easy on Pfizer.

In public comments Friday, FDA interim chief Les Crawford said the agency is concerned about the safety of the entire COX-2 drug class, adding that the FDA is recommending that doctors seek alternative therapies to Celebrex for their patients. This doesn't exactly sound like a guy who's looking for a top spot on Pfizer CEO Hank McKinnell's Christmas card list.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AZN $34.77 2.11%
CELG $110.56 1.01%
MRK $54.57 2.94%
PFE $33.62 2.59%
AAPL $117.34 -0.81%


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs